8-K: SELLAS Life Sciences Reports Q3 2026 Results, Advances AML Trials

SELLAS Life Sciences Group announced third quarter 2026 financial results, highlighting progress in its Phase 3 REGAL trial for GPS and Phase 2 trial for SLS009, alongside a robust cash reserve of $134.7 million.

Summary

• SELLAS Life Sciences Group reported its financial results for the third quarter ended September 30, 2026.
• The company is nearing topline primary endpoint results for its Phase 3 REGAL trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) following the 80th event.
• Enrollment and dosing are ongoing for the Phase 2 trial of SLS009 (tambiciclib) in newly diagnosed AML, with preliminary topline data expected in Q4 2026.
• Phase 2 data for SLS009 in relapsed/refractory AML showed a 54% ORR with a median overall survival of 5.8 months for monocytic AML and a 57% ORR with 8.8 months mOS for TP53-mutated AML.
• Preclinical data for SLS009 in pancreatic cancer models were presented, suggesting potential in combination therapies.
• Research and development expenses increased to $7.0 million for Q3 2026 from $4.2 million in Q3 2025.
• General and administrative expenses rose to $4.3 million for Q3 2026 from $2.9 million in Q3 2025.
• The net loss for Q3 2026 was $10.1 million, or $0.05 per share, compared to a net loss of $6.8 million, or $0.06 per share, in Q3 2025.
• As of September 30, 2026, the company held $134.7 million in cash and cash equivalents.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, with significant progress in clinical trials and a strong cash position, balanced by increasing operational expenses and continued net losses.

Positives

• Nearing topline primary endpoint results for the Phase 3 REGAL trial of GPS in AML this month.
• 40 patients enrolled in the Phase 2 trial of SLS009 in newly diagnosed AML, with preliminary data expected in Q4 2026.
• Positive Phase 2 data for SLS009 in relapsed/refractory AML, showing favorable ORR and mOS in specific patient subgroups compared to historical outcomes.
• Preclinical data presented for SLS009 in pancreatic cancer models, indicating potential for further development.
• Strong cash position of $134.7 million as of September 30, 2026, providing runway for program advancement.
• The company's lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center.

Negatives

• Net loss increased to $10.1 million in Q3 2026 from $6.8 million in Q3 2025.
• Research and development expenses increased significantly to $7.0 million in Q3 2026 from $4.2 million in Q3 2025.
• General and administrative expenses also increased to $4.3 million in Q3 2026 from $2.9 million in Q3 2025.
• Diluted loss per share was $0.05 in Q3 2026, compared to $0.06 in Q3 2025, indicating a worsening per-share loss despite a lower share count in the prior year's comparison.
• The weighted-average common shares outstanding increased significantly from 108,396,260 in Q3 2025 to 202,437,078 in Q3 2026.

Risks

• The uncertainty of regulatory approval for GPS and SLS009.
• Risks associated with oncology product development and clinical success.
• Potential for actual results to differ materially from forward-looking statements due to inherent risks and uncertainties.
• The company's reliance on future clinical trial results and regulatory outcomes.
• The possibility of unforeseen risks and uncertainties affecting the company's development programs.

Future Outlook

The company expects to announce topline primary endpoint results for the Phase 3 REGAL trial of GPS this month (November 2026). Preliminary topline data from the Phase 2 trial of SLS009 in newly diagnosed AML is expected in Q4 2026. The company is also preparing for clinical development of SLS009 in pancreatic cancer.

Management Comments

• "We continue to execute across both of our clinical programs as we approach several important milestones," said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS Life Sciences.
• "In our ongoing Phase 3 REGAL trial of GPS, we are focused on completing the final analysis following the announcement of 80th event, and we expect to announce topline primary endpoint results this month."
• "If successful, we believe GPS could be a transformative new immunotherapy for AML patients in second complete remission."
• "In parallel, enrollment and dosing continue in our Phase 2 trial of tambiciclib (SLS009) in newly diagnosed AML, with preliminary topline data expected in the fourth quarter."
• "We were also encouraged by the preclinical data presented at AACR in pancreatic cancer models, including in resistance to a RAS inhibitor, and we are continuing our preparations for clinical development in that indication."
• "With $134.7 million in cash and cash equivalents as of September 30, we are well positioned to further advance these programs."

Industry Context

StockSavvy.ai notes that SELLAS is operating in the highly competitive and capital-intensive biopharmaceutical sector, focusing on oncology. The company's progress with GPS and SLS009 aligns with industry trends towards targeted therapies and immunotherapies for difficult-to-treat cancers like AML and pancreatic cancer. The increasing R&D expenses reflect the significant investment required for late-stage clinical development and potential regulatory submissions.

Comparison to Industry Standards

• The reported ORR of 54% and 57% for SLS009 in relapsed/refractory AML, particularly in TP53-mutated AML (8.8 months mOS), compares favorably to historical outcomes in these adverse-risk settings, which are typically around 2.5 months median overall survival.
• The cash position of $134.7 million provides a runway that is generally considered adequate for a late-stage biopharmaceutical company of SELLAS's size, enabling continued progression of its clinical programs, though further funding may be required for later-stage commercialization or expanded development.

Stakeholder Impact

• Shareholders: The company's progress in clinical trials and strong cash position are positive indicators, but increased net losses and expenses may raise concerns about future dilution and profitability.
• Patients: Advancements in the GPS and SLS009 programs offer potential new treatment options for AML and other cancers.
• Employees: Continued investment in R&D and clinical trials suggests ongoing operational activity and potential for growth within the company.

Next Steps

• Announce topline primary endpoint results for the Phase 3 REGAL trial of GPS.
• Present Phase 2 data of SLS009 in relapsed/refractory AML at the 2026 ASH Annual Meeting.
• Report preliminary topline data from the Phase 2 trial of SLS009 in newly diagnosed AML.
• Continue preparations for clinical development of SLS009 in pancreatic cancer.

Key Dates

Recommendation

SELLAS Life Sciences Group is presenting progress in key clinical trials, particularly the nearing results for the Phase 3 REGAL trial of GPS, which could be a significant catalyst. The company also maintains a strong cash position. However, the increasing operational expenses and net losses, coupled with the inherent risks of drug development and regulatory approval, warrant a cautious 'hold' recommendation. Investors should await the topline results of the REGAL trial and further data from the SLS009 program before considering a more definitive stance.

Keywords

Acute Myeloid Leukemia, Galinpepimut-S, Galinpepimut-S (GPS), SLS009, tambiciclib, CDK9 inhibitor, Pancreatic cancer, Clinical trials